Details for New Drug Application (NDA): 217519
NDA 217519 describes TOBRAMYCIN SULFATE, which is a drug marketed by Apothecon, Baxter Hlthcare Corp, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland, Hainan Poly, Hikma, Hospira, Igi Labs Inc, Mylan Labs Ltd, Teva Pharms Usa, Watson Labs Inc, Xellia Pharms Aps, and Xgen Pharms, and is included in thirty-two NDAs. It is available from eleven suppliers. Additional details are available on the TOBRAMYCIN SULFATE profile page.
The generic ingredient in TOBRAMYCIN SULFATE is tobramycin sulfate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
The generic ingredient in TOBRAMYCIN SULFATE is tobramycin sulfate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
Summary for 217519
| Tradename: | TOBRAMYCIN SULFATE |
| Applicant: | Eugia Pharma |
| Ingredient: | tobramycin sulfate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 217519
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOBRAMYCIN SULFATE | tobramycin sulfate | INJECTABLE;INJECTION | 217519 | ANDA | Eugia US LLC | 55150-470 | 55150-470-06 | 6 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (55150-470-06) / 30 mL in 1 VIAL, PHARMACY BULK PACKAGE (55150-470-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1.2GM BASE/VIAL | ||||
| Approval Date: | Jun 21, 2023 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
